Thermo Fisher (TMO) announced 510(k) clearance of the Exent Analyser and Immunoglobulin Isotypes Assay, a first-of-its-kind automated platform for clinical laboratories.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher authorizes $5B of share repurchases
- Thermo Fisher’s Strategic Acquisition of Clario: Enhancing Clinical Trial Offerings and Driving Earnings Growth
- Thermo Fisher’s Strategic Acquisition of Clario: A Buy Rating with Promising Financial and Growth Prospects
- Thermo Fisher price target raised to $610 from $580 at Argus
- Thermo Fisher Announces Acquisition of Clario Holdings